Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 113 | 2025 | 11221 | 7.700 |
Why?
|
Urology | 28 | 2024 | 411 | 6.210 |
Why?
|
Cystectomy | 42 | 2024 | 645 | 5.980 |
Why?
|
Prostatectomy | 53 | 2024 | 1841 | 5.950 |
Why?
|
Medicare | 85 | 2025 | 6881 | 5.850 |
Why?
|
Urinary Bladder Neoplasms | 52 | 2024 | 2257 | 5.330 |
Why?
|
Surgicenters | 11 | 2016 | 50 | 4.010 |
Why?
|
Ambulatory Surgical Procedures | 15 | 2017 | 470 | 3.750 |
Why?
|
Nephrectomy | 23 | 2024 | 949 | 2.970 |
Why?
|
Urologic Surgical Procedures | 18 | 2024 | 299 | 2.770 |
Why?
|
Radiotherapy, Intensity-Modulated | 12 | 2017 | 812 | 2.580 |
Why?
|
Urinary Calculi | 9 | 2014 | 90 | 2.350 |
Why?
|
Quality of Health Care | 29 | 2024 | 4339 | 2.150 |
Why?
|
Robotics | 14 | 2013 | 825 | 1.930 |
Why?
|
United States | 142 | 2025 | 73150 | 1.850 |
Why?
|
Cost Savings | 10 | 2020 | 915 | 1.790 |
Why?
|
SEER Program | 30 | 2020 | 1474 | 1.780 |
Why?
|
Surgery Department, Hospital | 6 | 2014 | 176 | 1.770 |
Why?
|
Aged | 201 | 2025 | 171562 | 1.660 |
Why?
|
Laparoscopy | 20 | 2012 | 2056 | 1.590 |
Why?
|
Androstenes | 9 | 2024 | 186 | 1.500 |
Why?
|
Patient Readmission | 17 | 2024 | 3312 | 1.490 |
Why?
|
Kidney Neoplasms | 22 | 2024 | 4303 | 1.460 |
Why?
|
Diffusion of Innovation | 8 | 2014 | 732 | 1.360 |
Why?
|
Male | 261 | 2025 | 364902 | 1.340 |
Why?
|
Health Care Costs | 19 | 2020 | 3267 | 1.330 |
Why?
|
Phenylthiohydantoin | 8 | 2024 | 208 | 1.280 |
Why?
|
Ureteroscopy | 10 | 2011 | 150 | 1.280 |
Why?
|
Prostate | 15 | 2023 | 1781 | 1.200 |
Why?
|
Urinary Incontinence | 6 | 2023 | 496 | 1.190 |
Why?
|
Reimbursement Mechanisms | 7 | 2021 | 677 | 1.170 |
Why?
|
Reimbursement, Incentive | 8 | 2025 | 548 | 1.160 |
Why?
|
Surgical Procedures, Operative | 8 | 2024 | 1937 | 1.160 |
Why?
|
Kidney Calculi | 11 | 2018 | 469 | 1.160 |
Why?
|
Aged, 80 and over | 77 | 2025 | 59686 | 1.150 |
Why?
|
Prostate-Specific Antigen | 22 | 2024 | 2487 | 1.110 |
Why?
|
Androgen Receptor Antagonists | 2 | 2024 | 125 | 1.100 |
Why?
|
Humans | 324 | 2025 | 768393 | 1.090 |
Why?
|
Health Expenditures | 9 | 2024 | 2395 | 1.080 |
Why?
|
Ownership | 6 | 2023 | 344 | 1.080 |
Why?
|
Retrospective Studies | 86 | 2025 | 81801 | 1.060 |
Why?
|
Hospitals | 13 | 2024 | 3906 | 1.050 |
Why?
|
Prospective Payment System | 2 | 2022 | 136 | 1.050 |
Why?
|
Cost of Illness | 5 | 2014 | 1959 | 1.020 |
Why?
|
Watchful Waiting | 6 | 2025 | 499 | 1.000 |
Why?
|
Cystoscopy | 4 | 2015 | 132 | 0.990 |
Why?
|
Length of Stay | 20 | 2024 | 6519 | 0.990 |
Why?
|
Insurance, Health, Reimbursement | 2 | 2019 | 390 | 0.960 |
Why?
|
Suburethral Slings | 3 | 2013 | 72 | 0.900 |
Why?
|
Carcinoma, Renal Cell | 12 | 2022 | 3200 | 0.870 |
Why?
|
Certificate of Need | 2 | 2012 | 12 | 0.840 |
Why?
|
Erectile Dysfunction | 7 | 2023 | 445 | 0.840 |
Why?
|
Physicians | 9 | 2023 | 4614 | 0.820 |
Why?
|
Physician Self-Referral | 2 | 2014 | 18 | 0.810 |
Why?
|
Urinary Bladder, Overactive | 2 | 2015 | 119 | 0.810 |
Why?
|
Florida | 13 | 2019 | 430 | 0.810 |
Why?
|
Urinary Incontinence, Stress | 3 | 2013 | 182 | 0.780 |
Why?
|
Ureteral Calculi | 6 | 2003 | 117 | 0.760 |
Why?
|
Urologic Neoplasms | 4 | 2024 | 319 | 0.760 |
Why?
|
Regional Medical Programs | 2 | 2015 | 66 | 0.750 |
Why?
|
Nitriles | 9 | 2024 | 984 | 0.750 |
Why?
|
Unnecessary Procedures | 7 | 2018 | 419 | 0.740 |
Why?
|
Healthcare Disparities | 5 | 2024 | 3413 | 0.730 |
Why?
|
Urinary Retention | 4 | 2015 | 106 | 0.720 |
Why?
|
Hospitals, Teaching | 2 | 2024 | 1158 | 0.700 |
Why?
|
Neoplasm Staging | 24 | 2018 | 11254 | 0.700 |
Why?
|
Adrenergic alpha-Antagonists | 3 | 2013 | 174 | 0.690 |
Why?
|
Benzamides | 8 | 2024 | 1380 | 0.690 |
Why?
|
Urinary Bladder | 5 | 2022 | 1162 | 0.690 |
Why?
|
Drug Costs | 3 | 2025 | 1196 | 0.670 |
Why?
|
Economics, Hospital | 2 | 2019 | 210 | 0.670 |
Why?
|
Aortic Valve Stenosis | 3 | 2021 | 2034 | 0.660 |
Why?
|
Brachytherapy | 3 | 2023 | 1226 | 0.650 |
Why?
|
Health Services Misuse | 3 | 2012 | 249 | 0.640 |
Why?
|
Episode of Care | 1 | 2019 | 128 | 0.640 |
Why?
|
Postoperative Complications | 30 | 2024 | 15881 | 0.630 |
Why?
|
Nephrostomy, Percutaneous | 3 | 2015 | 79 | 0.630 |
Why?
|
Middle Aged | 129 | 2025 | 223491 | 0.630 |
Why?
|
Biomedical Technology | 1 | 2020 | 210 | 0.600 |
Why?
|
Quality Indicators, Health Care | 8 | 2015 | 1813 | 0.600 |
Why?
|
Electric Stimulation Therapy | 2 | 2015 | 636 | 0.600 |
Why?
|
Ambulatory Care Facilities | 2 | 2017 | 941 | 0.590 |
Why?
|
Health Care Reform | 5 | 2016 | 1262 | 0.590 |
Why?
|
Female | 132 | 2024 | 397089 | 0.580 |
Why?
|
Delivery of Health Care | 11 | 2023 | 5375 | 0.580 |
Why?
|
Vertebroplasty | 1 | 2018 | 79 | 0.580 |
Why?
|
Fee-for-Service Plans | 3 | 2021 | 714 | 0.580 |
Why?
|
Lymph Node Excision | 5 | 2013 | 1274 | 0.570 |
Why?
|
Recovery of Function | 8 | 2023 | 2990 | 0.570 |
Why?
|
Logistic Models | 24 | 2023 | 13323 | 0.560 |
Why?
|
Calcium Channel Blockers | 3 | 2013 | 692 | 0.560 |
Why?
|
Androgen Antagonists | 9 | 2024 | 1421 | 0.530 |
Why?
|
Ureter | 6 | 2017 | 370 | 0.530 |
Why?
|
Patient Discharge | 9 | 2019 | 3476 | 0.530 |
Why?
|
Renal Colic | 2 | 2013 | 29 | 0.530 |
Why?
|
Practice Management, Medical | 1 | 2017 | 192 | 0.510 |
Why?
|
Prostheses and Implants | 2 | 2013 | 1279 | 0.510 |
Why?
|
Cohort Studies | 30 | 2025 | 41795 | 0.500 |
Why?
|
Antineoplastic Agents | 11 | 2025 | 13697 | 0.490 |
Why?
|
Treatment Outcome | 55 | 2024 | 65379 | 0.480 |
Why?
|
Insurance Claim Review | 2 | 2017 | 746 | 0.480 |
Why?
|
Drug Industry | 2 | 2021 | 793 | 0.480 |
Why?
|
Endoscopy | 4 | 2013 | 1857 | 0.480 |
Why?
|
Kidney Pelvis | 4 | 2017 | 195 | 0.480 |
Why?
|
Quality Assurance, Health Care | 4 | 2013 | 2181 | 0.470 |
Why?
|
Guideline Adherence | 5 | 2019 | 2240 | 0.470 |
Why?
|
Office Visits | 1 | 2019 | 596 | 0.470 |
Why?
|
Hospital Administration | 2 | 2008 | 353 | 0.460 |
Why?
|
Electrocoagulation | 1 | 2015 | 153 | 0.460 |
Why?
|
Decision Support Techniques | 1 | 2024 | 2006 | 0.460 |
Why?
|
Fees and Charges | 2 | 2014 | 192 | 0.460 |
Why?
|
Patient Care Management | 1 | 2017 | 304 | 0.450 |
Why?
|
Ureteral Obstruction | 4 | 2017 | 297 | 0.450 |
Why?
|
Hospital Mortality | 10 | 2024 | 5367 | 0.450 |
Why?
|
Mitomycin | 1 | 2014 | 262 | 0.450 |
Why?
|
Diagnostic Imaging | 4 | 2014 | 3541 | 0.440 |
Why?
|
Technology Transfer | 1 | 2013 | 42 | 0.430 |
Why?
|
Medicare Part B | 1 | 2014 | 117 | 0.430 |
Why?
|
Electrodes, Implanted | 2 | 2015 | 841 | 0.430 |
Why?
|
Colectomy | 5 | 2021 | 699 | 0.410 |
Why?
|
Convalescence | 2 | 2016 | 109 | 0.410 |
Why?
|
Delivery of Health Care, Integrated | 3 | 2019 | 954 | 0.410 |
Why?
|
Health Care Sector | 1 | 2014 | 197 | 0.410 |
Why?
|
Quality of Life | 18 | 2022 | 13503 | 0.400 |
Why?
|
Heart Valve Prosthesis Implantation | 2 | 2019 | 1568 | 0.400 |
Why?
|
Medicare Part D | 4 | 2021 | 358 | 0.400 |
Why?
|
Gynecologic Surgical Procedures | 2 | 2012 | 289 | 0.400 |
Why?
|
Urolithiasis | 2 | 2013 | 125 | 0.390 |
Why?
|
Aftercare | 4 | 2018 | 921 | 0.380 |
Why?
|
Histocytological Preparation Techniques | 2 | 2001 | 33 | 0.360 |
Why?
|
Echocardiography, Stress | 1 | 2011 | 139 | 0.360 |
Why?
|
Alzheimer Disease | 2 | 2023 | 8747 | 0.360 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2014 | 677 | 0.360 |
Why?
|
Salvage Therapy | 4 | 2018 | 1277 | 0.360 |
Why?
|
Surgical Mesh | 1 | 2013 | 316 | 0.350 |
Why?
|
Risk Adjustment | 3 | 2019 | 603 | 0.350 |
Why?
|
Administration, Intravesical | 4 | 2011 | 92 | 0.350 |
Why?
|
Lithotripsy | 4 | 2011 | 141 | 0.340 |
Why?
|
Health Status | 5 | 2019 | 4094 | 0.340 |
Why?
|
Patient Admission | 4 | 2018 | 1367 | 0.330 |
Why?
|
Coronary Artery Bypass | 3 | 2021 | 2194 | 0.320 |
Why?
|
Colic | 1 | 2009 | 44 | 0.320 |
Why?
|
Radiotherapy, Conformal | 1 | 2012 | 549 | 0.320 |
Why?
|
Urogenital Neoplasms | 2 | 2024 | 133 | 0.310 |
Why?
|
Patient Satisfaction | 5 | 2021 | 3486 | 0.300 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2010 | 395 | 0.300 |
Why?
|
Health Resources | 1 | 2014 | 950 | 0.300 |
Why?
|
Fee Schedules | 1 | 2008 | 87 | 0.300 |
Why?
|
Time Factors | 23 | 2019 | 40272 | 0.300 |
Why?
|
Confidence Intervals | 6 | 2016 | 2931 | 0.300 |
Why?
|
Neoplasms | 8 | 2024 | 22385 | 0.300 |
Why?
|
Quality Improvement | 3 | 2019 | 3858 | 0.300 |
Why?
|
Prostatic Hyperplasia | 4 | 2013 | 523 | 0.290 |
Why?
|
Socioeconomic Factors | 8 | 2018 | 7861 | 0.290 |
Why?
|
Administration, Oral | 3 | 2024 | 4039 | 0.280 |
Why?
|
Kidney Diseases | 2 | 2009 | 2103 | 0.280 |
Why?
|
Ketoconazole | 2 | 2024 | 97 | 0.280 |
Why?
|
Biostatistics | 2 | 2019 | 165 | 0.280 |
Why?
|
Health Policy | 4 | 2024 | 2698 | 0.270 |
Why?
|
Drug Prescriptions | 4 | 2021 | 1673 | 0.270 |
Why?
|
Survivors | 4 | 2014 | 2382 | 0.270 |
Why?
|
Dementia | 1 | 2021 | 2729 | 0.270 |
Why?
|
Insurance Benefits | 2 | 2018 | 187 | 0.270 |
Why?
|
Delayed Diagnosis | 1 | 2010 | 469 | 0.270 |
Why?
|
Pneumonectomy | 2 | 2018 | 1158 | 0.260 |
Why?
|
Internship and Residency | 3 | 2022 | 5949 | 0.260 |
Why?
|
Cataract Extraction | 1 | 2010 | 465 | 0.260 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2022 | 9433 | 0.260 |
Why?
|
Centralized Hospital Services | 1 | 2005 | 18 | 0.260 |
Why?
|
Carcinoma in Situ | 1 | 2011 | 789 | 0.260 |
Why?
|
Adult | 57 | 2024 | 223640 | 0.250 |
Why?
|
Learning | 1 | 2015 | 1761 | 0.250 |
Why?
|
Androgens | 4 | 2024 | 1285 | 0.250 |
Why?
|
Fear | 1 | 2014 | 1494 | 0.250 |
Why?
|
Regional Health Planning | 1 | 2005 | 96 | 0.240 |
Why?
|
Motivation | 3 | 2023 | 2029 | 0.240 |
Why?
|
Arthroplasty, Replacement, Knee | 4 | 2019 | 1402 | 0.240 |
Why?
|
Radiation Injuries | 1 | 2012 | 1204 | 0.240 |
Why?
|
Rhinitis | 1 | 2012 | 751 | 0.240 |
Why?
|
Neoadjuvant Therapy | 5 | 2022 | 2909 | 0.240 |
Why?
|
Hospital Costs | 3 | 2018 | 959 | 0.230 |
Why?
|
Models, Theoretical | 5 | 2019 | 3579 | 0.230 |
Why?
|
Orgasm | 1 | 2004 | 63 | 0.230 |
Why?
|
Databases, Factual | 12 | 2018 | 8075 | 0.230 |
Why?
|
Intraoperative Care | 1 | 2008 | 771 | 0.230 |
Why?
|
Odds Ratio | 11 | 2019 | 9682 | 0.230 |
Why?
|
Testicular Neoplasms | 2 | 2007 | 805 | 0.230 |
Why?
|
Neoplasm Invasiveness | 7 | 2020 | 3633 | 0.220 |
Why?
|
Referral and Consultation | 6 | 2018 | 3627 | 0.220 |
Why?
|
Urethra | 1 | 2006 | 406 | 0.220 |
Why?
|
Pelvis | 1 | 2008 | 738 | 0.220 |
Why?
|
Esophagectomy | 1 | 2007 | 482 | 0.220 |
Why?
|
Michigan | 5 | 2025 | 341 | 0.220 |
Why?
|
Age Factors | 11 | 2019 | 18471 | 0.220 |
Why?
|
Arthroscopy | 1 | 2010 | 971 | 0.220 |
Why?
|
Benchmarking | 2 | 2007 | 1058 | 0.220 |
Why?
|
Laser Therapy | 4 | 2013 | 1105 | 0.220 |
Why?
|
Sinusitis | 1 | 2012 | 995 | 0.210 |
Why?
|
Group Practice | 2 | 2021 | 151 | 0.210 |
Why?
|
Molecular Targeted Therapy | 2 | 2025 | 2830 | 0.210 |
Why?
|
Decision Making | 3 | 2019 | 3953 | 0.210 |
Why?
|
Hysterectomy | 1 | 2008 | 864 | 0.210 |
Why?
|
Survival Rate | 11 | 2017 | 12870 | 0.200 |
Why?
|
Surgery, Computer-Assisted | 1 | 2010 | 1006 | 0.200 |
Why?
|
Survival Analysis | 8 | 2018 | 10117 | 0.200 |
Why?
|
Sex | 1 | 2002 | 53 | 0.200 |
Why?
|
Transurethral Resection of Prostate | 2 | 2013 | 81 | 0.200 |
Why?
|
Colonoscopy | 1 | 2010 | 1412 | 0.200 |
Why?
|
Regression Analysis | 6 | 2021 | 6350 | 0.200 |
Why?
|
Abdomen | 1 | 2008 | 1136 | 0.200 |
Why?
|
Cost-Benefit Analysis | 7 | 2019 | 5538 | 0.200 |
Why?
|
Penile Prosthesis | 1 | 2002 | 33 | 0.200 |
Why?
|
Emergency Service, Hospital | 4 | 2018 | 7955 | 0.190 |
Why?
|
Health Services Research | 4 | 2015 | 1817 | 0.190 |
Why?
|
Medication Adherence | 3 | 2020 | 2189 | 0.190 |
Why?
|
Seminal Vesicles | 2 | 2022 | 103 | 0.190 |
Why?
|
Mass Screening | 3 | 2019 | 5451 | 0.190 |
Why?
|
Lithotripsy, Laser | 2 | 2002 | 45 | 0.190 |
Why?
|
Workload | 1 | 2007 | 852 | 0.190 |
Why?
|
Proportional Hazards Models | 9 | 2016 | 12558 | 0.190 |
Why?
|
Hospital-Physician Joint Ventures | 1 | 2021 | 31 | 0.180 |
Why?
|
Utilization Review | 3 | 2007 | 384 | 0.180 |
Why?
|
Medical Oncology | 3 | 2024 | 2349 | 0.180 |
Why?
|
Prognosis | 17 | 2024 | 30022 | 0.180 |
Why?
|
Hormones | 2 | 2023 | 870 | 0.180 |
Why?
|
Genetic Testing | 2 | 2024 | 3587 | 0.180 |
Why?
|
Models, Anatomic | 1 | 2024 | 684 | 0.180 |
Why?
|
Risk | 5 | 2015 | 9636 | 0.180 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2004 | 365 | 0.180 |
Why?
|
Neuroendocrine Cells | 1 | 2021 | 62 | 0.170 |
Why?
|
Health Care Surveys | 4 | 2019 | 2437 | 0.170 |
Why?
|
Perioperative Care | 2 | 2014 | 1045 | 0.170 |
Why?
|
Kaplan-Meier Estimate | 7 | 2024 | 6541 | 0.170 |
Why?
|
Risk Assessment | 15 | 2024 | 24318 | 0.170 |
Why?
|
Costs and Cost Analysis | 3 | 2020 | 1669 | 0.170 |
Why?
|
Cell Transdifferentiation | 1 | 2021 | 187 | 0.170 |
Why?
|
Algorithms | 5 | 2018 | 14154 | 0.170 |
Why?
|
Disease-Free Survival | 6 | 2023 | 6856 | 0.170 |
Why?
|
Urination Disorders | 2 | 2011 | 238 | 0.170 |
Why?
|
Urinary Diversion | 3 | 2017 | 137 | 0.160 |
Why?
|
Guidelines as Topic | 2 | 2018 | 1397 | 0.160 |
Why?
|
Patient-Centered Care | 3 | 2021 | 1447 | 0.160 |
Why?
|
Biomedical Research | 3 | 2019 | 3464 | 0.160 |
Why?
|
Mortality | 4 | 2018 | 2917 | 0.160 |
Why?
|
Castration | 1 | 2018 | 150 | 0.160 |
Why?
|
Health Services Accessibility | 4 | 2011 | 5512 | 0.160 |
Why?
|
Carcinoma | 2 | 2013 | 2341 | 0.160 |
Why?
|
Policy | 1 | 2022 | 514 | 0.160 |
Why?
|
Adolescent | 16 | 2018 | 89184 | 0.150 |
Why?
|
Registries | 8 | 2023 | 8379 | 0.150 |
Why?
|
Receptors, Androgen | 1 | 2024 | 1083 | 0.150 |
Why?
|
Orchiectomy | 2 | 2018 | 466 | 0.150 |
Why?
|
Pain, Postoperative | 2 | 2016 | 1765 | 0.150 |
Why?
|
Arthroplasty, Replacement, Hip | 2 | 2019 | 1421 | 0.150 |
Why?
|
Cross-Over Studies | 1 | 2024 | 2106 | 0.150 |
Why?
|
Poisson Distribution | 2 | 2009 | 509 | 0.150 |
Why?
|
Periodicals as Topic | 2 | 2019 | 1469 | 0.140 |
Why?
|
Young Adult | 14 | 2018 | 60049 | 0.140 |
Why?
|
Lymph Nodes | 2 | 2013 | 3471 | 0.140 |
Why?
|
Organ Transplantation | 1 | 2007 | 1177 | 0.140 |
Why?
|
Evidence-Based Medicine | 1 | 2009 | 3707 | 0.140 |
Why?
|
Biopsy | 6 | 2016 | 6808 | 0.140 |
Why?
|
Primary Health Care | 2 | 2010 | 4748 | 0.140 |
Why?
|
Diagnosis-Related Groups | 2 | 2010 | 448 | 0.130 |
Why?
|
Prosthesis Failure | 1 | 2002 | 1208 | 0.130 |
Why?
|
Follow-Up Studies | 15 | 2018 | 39407 | 0.130 |
Why?
|
Hospital Bed Capacity | 2 | 2008 | 206 | 0.130 |
Why?
|
Sexual Behavior | 2 | 2015 | 2200 | 0.130 |
Why?
|
Veterans | 2 | 2021 | 2671 | 0.130 |
Why?
|
Germ-Line Mutation | 1 | 2024 | 1885 | 0.130 |
Why?
|
Chi-Square Distribution | 3 | 2011 | 3438 | 0.130 |
Why?
|
Multivariate Analysis | 8 | 2018 | 12092 | 0.130 |
Why?
|
Subacute Care | 1 | 2018 | 188 | 0.130 |
Why?
|
Urologic Diseases | 1 | 2018 | 247 | 0.130 |
Why?
|
Sexual Partners | 2 | 2021 | 806 | 0.120 |
Why?
|
Lumbosacral Plexus | 1 | 2015 | 54 | 0.120 |
Why?
|
Physician's Role | 2 | 2016 | 926 | 0.120 |
Why?
|
Research Design | 4 | 2019 | 6210 | 0.120 |
Why?
|
Program Evaluation | 2 | 2018 | 2505 | 0.120 |
Why?
|
Diagnostic Techniques, Urological | 2 | 2014 | 29 | 0.120 |
Why?
|
Cancer Care Facilities | 1 | 2017 | 424 | 0.120 |
Why?
|
Medicine | 2 | 2013 | 948 | 0.120 |
Why?
|
Depression | 1 | 2014 | 8241 | 0.120 |
Why?
|
Nephrons | 2 | 2009 | 168 | 0.120 |
Why?
|
Prospective Studies | 12 | 2024 | 54920 | 0.120 |
Why?
|
Hospice Care | 1 | 2021 | 679 | 0.120 |
Why?
|
Myocardial Revascularization | 1 | 2018 | 796 | 0.110 |
Why?
|
Neoplasm Metastasis | 3 | 2024 | 4921 | 0.110 |
Why?
|
Tissue Adhesives | 2 | 2006 | 179 | 0.110 |
Why?
|
Drug Utilization | 2 | 2010 | 1191 | 0.110 |
Why?
|
Adrenergic alpha-1 Receptor Antagonists | 1 | 2013 | 24 | 0.110 |
Why?
|
Adenocarcinoma | 4 | 2018 | 6406 | 0.110 |
Why?
|
Interinstitutional Relations | 1 | 2015 | 236 | 0.110 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2014 | 799 | 0.110 |
Why?
|
Terminal Care | 2 | 2024 | 1773 | 0.110 |
Why?
|
Cross-Sectional Studies | 7 | 2022 | 26375 | 0.110 |
Why?
|
Stents | 3 | 2002 | 3201 | 0.110 |
Why?
|
Radiosurgery | 1 | 2022 | 1346 | 0.100 |
Why?
|
Ureteral Neoplasms | 1 | 2013 | 108 | 0.100 |
Why?
|
Tomography, X-Ray Computed | 4 | 2018 | 20765 | 0.100 |
Why?
|
Risk Factors | 14 | 2023 | 74962 | 0.100 |
Why?
|
Practice Guidelines as Topic | 4 | 2024 | 7453 | 0.100 |
Why?
|
Geography | 2 | 2021 | 654 | 0.100 |
Why?
|
Probability | 3 | 2008 | 2482 | 0.100 |
Why?
|
Urethral Stricture | 1 | 2011 | 51 | 0.100 |
Why?
|
Aortic Aneurysm, Abdominal | 2 | 2019 | 1252 | 0.100 |
Why?
|
Urothelium | 1 | 2013 | 276 | 0.090 |
Why?
|
Living Donors | 2 | 2008 | 651 | 0.090 |
Why?
|
Sacrum | 1 | 2013 | 275 | 0.090 |
Why?
|
Efficiency, Organizational | 2 | 2021 | 700 | 0.090 |
Why?
|
Analysis of Variance | 4 | 2017 | 6241 | 0.090 |
Why?
|
Urinary Bladder Diseases | 1 | 2011 | 167 | 0.090 |
Why?
|
Managed Care Programs | 2 | 2014 | 942 | 0.090 |
Why?
|
Secondary Prevention | 2 | 2015 | 1476 | 0.090 |
Why?
|
Life Expectancy | 2 | 2018 | 1249 | 0.090 |
Why?
|
Vaccinia virus | 2 | 2010 | 330 | 0.090 |
Why?
|
HLA-A2 Antigen | 1 | 2010 | 208 | 0.080 |
Why?
|
Insurance Coverage | 2 | 2020 | 1946 | 0.080 |
Why?
|
Clinical Competence | 2 | 2013 | 4848 | 0.080 |
Why?
|
State Government | 1 | 2012 | 389 | 0.080 |
Why?
|
Psychometrics | 2 | 2010 | 3069 | 0.080 |
Why?
|
Outpatients | 1 | 2017 | 1604 | 0.080 |
Why?
|
Patient Participation | 1 | 2018 | 1448 | 0.080 |
Why?
|
Peripheral Nerves | 1 | 2013 | 492 | 0.080 |
Why?
|
Data Interpretation, Statistical | 1 | 2019 | 2708 | 0.080 |
Why?
|
Medicaid | 4 | 2021 | 2842 | 0.080 |
Why?
|
United States Department of Veterans Affairs | 3 | 2019 | 940 | 0.080 |
Why?
|
Incidence | 7 | 2021 | 21544 | 0.080 |
Why?
|
Taxoids | 2 | 2023 | 668 | 0.080 |
Why?
|
Combined Modality Therapy | 5 | 2019 | 8562 | 0.080 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2015 | 957 | 0.080 |
Why?
|
Tumor Burden | 1 | 2014 | 1913 | 0.080 |
Why?
|
Preoperative Care | 2 | 2010 | 2258 | 0.070 |
Why?
|
Osteoporosis | 1 | 2017 | 1606 | 0.070 |
Why?
|
Suture Techniques | 3 | 2011 | 777 | 0.070 |
Why?
|
Diagnostic Services | 1 | 2007 | 34 | 0.070 |
Why?
|
Medical Record Linkage | 1 | 2009 | 286 | 0.070 |
Why?
|
Myocardial Ischemia | 1 | 2018 | 2139 | 0.070 |
Why?
|
Reoperation | 2 | 2012 | 4341 | 0.070 |
Why?
|
Advisory Committees | 1 | 2011 | 797 | 0.070 |
Why?
|
Health Facility Size | 1 | 2007 | 61 | 0.070 |
Why?
|
Antigens, Polyomavirus Transforming | 1 | 2008 | 257 | 0.070 |
Why?
|
Diagnostic Tests, Routine | 1 | 2013 | 790 | 0.070 |
Why?
|
Predictive Value of Tests | 4 | 2024 | 15455 | 0.070 |
Why?
|
Databases as Topic | 1 | 2009 | 475 | 0.070 |
Why?
|
Deductibles and Coinsurance | 1 | 2009 | 316 | 0.070 |
Why?
|
Early Detection of Cancer | 2 | 2018 | 3236 | 0.070 |
Why?
|
Kidney Transplantation | 3 | 2007 | 4300 | 0.070 |
Why?
|
Hospitals, Proprietary | 1 | 2006 | 39 | 0.070 |
Why?
|
Positron-Emission Tomography | 2 | 2013 | 6670 | 0.070 |
Why?
|
Health Status Indicators | 2 | 2010 | 971 | 0.070 |
Why?
|
Blood Loss, Surgical | 1 | 2010 | 643 | 0.070 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2024 | 3553 | 0.070 |
Why?
|
Bone Neoplasms | 1 | 2018 | 2565 | 0.070 |
Why?
|
Patient Selection | 3 | 2017 | 4266 | 0.060 |
Why?
|
Autoantigens | 1 | 2010 | 891 | 0.060 |
Why?
|
Models, Organizational | 1 | 2009 | 548 | 0.060 |
Why?
|
Attitude of Health Personnel | 1 | 2019 | 3922 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 3 | 2023 | 36849 | 0.060 |
Why?
|
Focus Groups | 2 | 2010 | 1453 | 0.060 |
Why?
|
Observation | 1 | 2007 | 311 | 0.060 |
Why?
|
Colonic Neoplasms | 2 | 2007 | 2544 | 0.060 |
Why?
|
Ileus | 1 | 2005 | 66 | 0.060 |
Why?
|
Fractures, Bone | 1 | 2017 | 2062 | 0.060 |
Why?
|
Laparoscopes | 1 | 2005 | 37 | 0.060 |
Why?
|
Patient Education as Topic | 1 | 2015 | 2337 | 0.060 |
Why?
|
Organ Size | 1 | 2010 | 2268 | 0.060 |
Why?
|
Fibrin Tissue Adhesive | 1 | 2005 | 87 | 0.060 |
Why?
|
Transplants | 1 | 2007 | 208 | 0.060 |
Why?
|
Hospitalization | 5 | 2020 | 10844 | 0.060 |
Why?
|
Residence Characteristics | 1 | 2015 | 2122 | 0.060 |
Why?
|
Sex Distribution | 1 | 2009 | 2281 | 0.060 |
Why?
|
Superior Mesenteric Artery Syndrome | 1 | 2004 | 7 | 0.060 |
Why?
|
Hospitals, Urban | 1 | 2006 | 500 | 0.060 |
Why?
|
Life Tables | 1 | 2004 | 368 | 0.060 |
Why?
|
Pilot Projects | 3 | 2018 | 8731 | 0.060 |
Why?
|
Personal Satisfaction | 2 | 2021 | 647 | 0.060 |
Why?
|
Models, Economic | 2 | 2018 | 718 | 0.060 |
Why?
|
Employment | 1 | 2010 | 1116 | 0.060 |
Why?
|
Editorial Policies | 2 | 2019 | 459 | 0.060 |
Why?
|
Hospitals, Rural | 1 | 2005 | 176 | 0.060 |
Why?
|
Cumulative Trauma Disorders | 1 | 2005 | 153 | 0.050 |
Why?
|
Qualitative Research | 2 | 2019 | 3131 | 0.050 |
Why?
|
Postoperative Care | 1 | 2010 | 1480 | 0.050 |
Why?
|
Population Surveillance | 1 | 2014 | 2598 | 0.050 |
Why?
|
Intraoperative Complications | 4 | 2005 | 1176 | 0.050 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2011 | 1614 | 0.050 |
Why?
|
Insemination, Artificial, Homologous | 1 | 2002 | 17 | 0.050 |
Why?
|
Operating Rooms | 1 | 2009 | 799 | 0.050 |
Why?
|
Antibiotic Prophylaxis | 1 | 2008 | 640 | 0.050 |
Why?
|
Specialties, Surgical | 1 | 2007 | 393 | 0.050 |
Why?
|
Neuromuscular Diseases | 1 | 2005 | 261 | 0.050 |
Why?
|
Skilled Nursing Facilities | 1 | 2006 | 406 | 0.050 |
Why?
|
Electronic Health Records | 1 | 2020 | 4875 | 0.050 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2017 | 2442 | 0.050 |
Why?
|
Fiber Optic Technology | 1 | 2003 | 291 | 0.050 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2018 | 1794 | 0.050 |
Why?
|
Sperm Count | 1 | 2002 | 229 | 0.050 |
Why?
|
Coitus | 1 | 2002 | 133 | 0.050 |
Why?
|
Treatment Failure | 2 | 2018 | 2663 | 0.050 |
Why?
|
Sperm Motility | 1 | 2002 | 266 | 0.050 |
Why?
|
Sepsis | 1 | 2015 | 2601 | 0.050 |
Why?
|
Health Services Needs and Demand | 1 | 2009 | 1407 | 0.050 |
Why?
|
Kidney Failure, Chronic | 1 | 2013 | 2491 | 0.050 |
Why?
|
Hernia, Inguinal | 1 | 2004 | 225 | 0.050 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2010 | 1189 | 0.040 |
Why?
|
Telemedicine | 1 | 2018 | 3107 | 0.040 |
Why?
|
Morbidity | 1 | 2006 | 1758 | 0.040 |
Why?
|
Histoplasmosis | 1 | 2000 | 63 | 0.040 |
Why?
|
Cancer Vaccines | 1 | 2008 | 1042 | 0.040 |
Why?
|
Testicular Diseases | 1 | 2000 | 73 | 0.040 |
Why?
|
Patient Acceptance of Health Care | 2 | 2024 | 3231 | 0.040 |
Why?
|
Social Class | 1 | 2009 | 2009 | 0.040 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 3252 | 0.040 |
Why?
|
Home Care Services | 1 | 2006 | 659 | 0.040 |
Why?
|
Health Status Disparities | 1 | 2011 | 1882 | 0.040 |
Why?
|
Semen | 1 | 2002 | 349 | 0.040 |
Why?
|
Bacterial Infections | 1 | 2008 | 1397 | 0.040 |
Why?
|
Income | 2 | 2020 | 1877 | 0.040 |
Why?
|
Neurilemmoma | 1 | 2004 | 524 | 0.040 |
Why?
|
Commerce | 1 | 2024 | 612 | 0.040 |
Why?
|
Immune Tolerance | 1 | 2008 | 2324 | 0.040 |
Why?
|
Safety | 1 | 2003 | 1159 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2018 | 6971 | 0.040 |
Why?
|
Sensitivity and Specificity | 3 | 2018 | 14737 | 0.040 |
Why?
|
General Surgery | 1 | 2010 | 1713 | 0.040 |
Why?
|
Copying Processes | 1 | 2018 | 5 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 11854 | 0.040 |
Why?
|
Acute Kidney Injury | 2 | 2013 | 1943 | 0.040 |
Why?
|
Immunotherapy, Adoptive | 1 | 2008 | 1508 | 0.040 |
Why?
|
Child | 4 | 2014 | 80891 | 0.040 |
Why?
|
Private Sector | 1 | 2021 | 396 | 0.040 |
Why?
|
Chronic Disease | 1 | 2012 | 9379 | 0.040 |
Why?
|
Intestine, Small | 1 | 2004 | 1218 | 0.040 |
Why?
|
Adrenal Cortex Hormones | 1 | 2006 | 1890 | 0.040 |
Why?
|
Severity of Illness Index | 2 | 2014 | 15939 | 0.040 |
Why?
|
Case-Control Studies | 3 | 2019 | 22296 | 0.040 |
Why?
|
Myocardial Infarction | 1 | 2018 | 11516 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2022 | 10377 | 0.040 |
Why?
|
Infant | 2 | 2009 | 36510 | 0.040 |
Why?
|
Esophageal Neoplasms | 1 | 2007 | 1676 | 0.030 |
Why?
|
Hematoma | 1 | 2002 | 768 | 0.030 |
Why?
|
Occupational Diseases | 1 | 2005 | 1490 | 0.030 |
Why?
|
Child, Preschool | 2 | 2009 | 42650 | 0.030 |
Why?
|
RNA, Messenger | 1 | 2011 | 12805 | 0.030 |
Why?
|
Hospital Communication Systems | 1 | 2016 | 48 | 0.030 |
Why?
|
Radiography | 3 | 2002 | 6993 | 0.030 |
Why?
|
Specimen Handling | 1 | 2000 | 708 | 0.030 |
Why?
|
Failure to Thrive | 1 | 2016 | 140 | 0.030 |
Why?
|
Homeodomain Proteins | 1 | 2024 | 2429 | 0.030 |
Why?
|
Ischemia | 1 | 2004 | 1900 | 0.030 |
Why?
|
Endpoint Determination | 1 | 2018 | 594 | 0.030 |
Why?
|
Postoperative Period | 1 | 2020 | 1830 | 0.030 |
Why?
|
Oncology Service, Hospital | 1 | 2014 | 57 | 0.030 |
Why?
|
Prosthesis Design | 1 | 2002 | 2126 | 0.030 |
Why?
|
Preoperative Period | 1 | 2017 | 564 | 0.030 |
Why?
|
Health Surveys | 1 | 2004 | 4056 | 0.030 |
Why?
|
Research Personnel | 1 | 2019 | 590 | 0.030 |
Why?
|
Heart Failure | 1 | 2018 | 11858 | 0.030 |
Why?
|
Laparotomy | 1 | 2016 | 459 | 0.030 |
Why?
|
Kidney Tubular Necrosis, Acute | 1 | 2013 | 65 | 0.030 |
Why?
|
Reproducibility of Results | 2 | 2010 | 20224 | 0.030 |
Why?
|
Biopsy, Needle | 1 | 2018 | 1627 | 0.030 |
Why?
|
Clinical Protocols | 1 | 2018 | 1445 | 0.030 |
Why?
|
Propensity Score | 1 | 2020 | 1962 | 0.030 |
Why?
|
Models, Biological | 1 | 2009 | 9493 | 0.030 |
Why?
|
T-Lymphocytes | 1 | 2010 | 10267 | 0.030 |
Why?
|
Alcohol Drinking | 1 | 2005 | 4049 | 0.030 |
Why?
|
Comorbidity | 3 | 2016 | 10588 | 0.020 |
Why?
|
Intention to Treat Analysis | 1 | 2013 | 417 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 4588 | 0.020 |
Why?
|
Needs Assessment | 1 | 2018 | 1142 | 0.020 |
Why?
|
Matched-Pair Analysis | 1 | 2012 | 286 | 0.020 |
Why?
|
Pregnancy Outcome | 1 | 2002 | 2961 | 0.020 |
Why?
|
Republic of Korea | 1 | 2013 | 587 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2019 | 2740 | 0.020 |
Why?
|
Physicians, Primary Care | 1 | 2018 | 623 | 0.020 |
Why?
|
Obesity, Morbid | 1 | 2002 | 1309 | 0.020 |
Why?
|
Patient Preference | 1 | 2018 | 947 | 0.020 |
Why?
|
Hematuria | 1 | 2011 | 233 | 0.020 |
Why?
|
Dilatation | 1 | 2011 | 313 | 0.020 |
Why?
|
Carboplatin | 1 | 2013 | 799 | 0.020 |
Why?
|
Insurance, Health | 2 | 2013 | 2518 | 0.020 |
Why?
|
Intestines | 2 | 2011 | 1912 | 0.020 |
Why?
|
Ambulatory Care | 1 | 2021 | 2784 | 0.020 |
Why?
|
Congresses as Topic | 1 | 2014 | 810 | 0.020 |
Why?
|
Kidney Function Tests | 1 | 2011 | 681 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2009 | 26411 | 0.020 |
Why?
|
Urinary Tract Infections | 1 | 2015 | 806 | 0.020 |
Why?
|
Fever | 1 | 2016 | 1620 | 0.020 |
Why?
|
Disease Management | 1 | 2019 | 2537 | 0.020 |
Why?
|
Deoxycytidine | 1 | 2013 | 888 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2024 | 9510 | 0.020 |
Why?
|
Anastomosis, Surgical | 1 | 2011 | 993 | 0.020 |
Why?
|
Neutropenia | 1 | 2013 | 893 | 0.020 |
Why?
|
Blotting, Southern | 1 | 2008 | 777 | 0.020 |
Why?
|
Neoplasm, Residual | 1 | 2013 | 1019 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2017 | 2168 | 0.020 |
Why?
|
Factor Analysis, Statistical | 1 | 2010 | 1004 | 0.020 |
Why?
|
Acute Disease | 1 | 2018 | 7242 | 0.020 |
Why?
|
Radiotherapy | 1 | 2014 | 1509 | 0.020 |
Why?
|
Testosterone | 1 | 2018 | 2493 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2023 | 14784 | 0.020 |
Why?
|
Europe | 1 | 2013 | 3439 | 0.020 |
Why?
|
Pain | 1 | 2002 | 5103 | 0.020 |
Why?
|
Obesity | 2 | 2006 | 13084 | 0.020 |
Why?
|
Hypertension | 1 | 2006 | 8615 | 0.020 |
Why?
|
Immunization | 1 | 2010 | 1219 | 0.020 |
Why?
|
Pain Measurement | 1 | 2016 | 3581 | 0.020 |
Why?
|
Surgical Instruments | 1 | 2008 | 386 | 0.020 |
Why?
|
Paclitaxel | 1 | 2013 | 1736 | 0.020 |
Why?
|
Recurrence | 1 | 2018 | 8506 | 0.020 |
Why?
|
Thrombocytopenia | 1 | 2013 | 1180 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2008 | 1705 | 0.020 |
Why?
|
Bone Density | 1 | 2017 | 3559 | 0.010 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2008 | 1355 | 0.010 |
Why?
|
Neoplasm Transplantation | 1 | 2008 | 2017 | 0.010 |
Why?
|
Decision Trees | 1 | 2005 | 509 | 0.010 |
Why?
|
Scrotum | 1 | 2004 | 118 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 3813 | 0.010 |
Why?
|
Mice, SCID | 1 | 2008 | 2632 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2007 | 13576 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2024 | 18048 | 0.010 |
Why?
|
Disability Evaluation | 1 | 2010 | 1838 | 0.010 |
Why?
|
Critical Care | 1 | 2015 | 2716 | 0.010 |
Why?
|
Hand Injuries | 1 | 2005 | 240 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2010 | 3164 | 0.010 |
Why?
|
Intensive Care Units | 1 | 2015 | 3801 | 0.010 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2008 | 1795 | 0.010 |
Why?
|
Blotting, Western | 1 | 2008 | 5037 | 0.010 |
Why?
|
Infection Control | 1 | 2008 | 985 | 0.010 |
Why?
|
Short Bowel Syndrome | 1 | 2004 | 353 | 0.010 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2008 | 3617 | 0.010 |
Why?
|
Lymphatic Metastasis | 1 | 2007 | 2925 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2010 | 5900 | 0.010 |
Why?
|
Necrosis | 1 | 2004 | 1621 | 0.010 |
Why?
|
Infertility, Male | 1 | 2002 | 397 | 0.010 |
Why?
|
Dendritic Cells | 1 | 2010 | 2749 | 0.010 |
Why?
|
Surgical Wound Infection | 1 | 2008 | 1545 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2008 | 6510 | 0.010 |
Why?
|
Accidents, Traffic | 1 | 2004 | 819 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2010 | 9562 | 0.010 |
Why?
|
Body Mass Index | 2 | 2006 | 13052 | 0.010 |
Why?
|
Infertility, Female | 1 | 2002 | 765 | 0.010 |
Why?
|
Prevalence | 1 | 2013 | 15872 | 0.010 |
Why?
|
Swine | 1 | 2006 | 5994 | 0.010 |
Why?
|
Immunotherapy | 1 | 2010 | 4738 | 0.010 |
Why?
|
Equipment Design | 1 | 2002 | 3529 | 0.010 |
Why?
|
Tissue Donors | 1 | 2002 | 2389 | 0.010 |
Why?
|
Mice | 2 | 2010 | 82017 | 0.010 |
Why?
|
Animals | 3 | 2010 | 169337 | 0.010 |
Why?
|
Body Weight | 1 | 2002 | 4629 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2008 | 17135 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2008 | 22355 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2008 | 7463 | 0.010 |
Why?
|
Kidney | 1 | 2002 | 7064 | 0.000 |
Why?
|
Disease Models, Animal | 1 | 2006 | 18362 | 0.000 |
Why?
|
Pregnancy | 1 | 2002 | 30200 | 0.000 |
Why?
|